2Ferguson GT, Chemiak P.M. Management of chronic obstructive pulmonary disease [J]. N Engl J Med, 1993, 328:1017 -1022.
3Jones PW, Quirk FH, Baveystock CM, et al. A self - complete measure of health status for chronic airflow limitation: the ST George's resp iratory questionnaire [ J]. Am Rev Resp irDis, 1992, 145:773 -778.
4Global Initiative for Chronic Obstructive Lung Disease [ J]. Globalstrategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: executive summary ( updated 2004 ) : 11 (01) : 26 - 28.
5TASHKIN DP, COOPER CB. The role of long - acting bron - chodilatots in the management of stable COPD [J]. Chest, 2004, 125:249 - 259.
6Pinto - Plata VM, Cote C, Cabral H, et al. The 6 - minwalk distance: change over time and value as a predictor of survival in severe COPD [J]. EurRespirJ, 2004, 23: 28-33.
8Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther, 2007, 20:495-502.
9Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva) : mechanistical considerations and clinical profile in obstructive lung disease. Life Sci, 1999, 64:457-464.
10Barnes PJ. The pharmacological properties of tiotropium. Chest, 2000, 117(2 suppl) :63S-66S.
